Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIFEMME vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation,Treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with an IDH1 mutation
Prevention of pregnancy (FDA-approved)
Subcutaneous injection: 0.5 m L (15 mg) once weekly.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 24-30 hours, allowing once-daily dosing for treatment of relapsed/refractory multiple myeloma.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily metabolized by CYP3A4 and CYP2C8. Minor contribution from CYP2D6.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily unchanged in feces (approx. 60-70%) via biliary excretion, with renal excretion accounting for <10% of the dose.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
Vd/F is 20-30 L (approx. 0.3-0.5 L/kg), indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Approximately 50% (range 30-80%) following oral administration; food decreases AUC by 30% and Cmax by 50%, but no dose adjustment required.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in pediatric patients (<18 years).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No dose adjustment required; however, caution is advised due to potentially decreased renal function. Monitor renal function in elderly patients.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
WARNING: QTc PROLONGATION AND RISK OF TORSADE DE POINTES Elifemme causes concentration-dependent QTc interval prolongation. Avoid use in patients with baseline QTc > 470 msec or with factors predisposing to prolonged QTc. Monitor ECG before initiation, after each dose escalation, and periodically during treatment. Correct electrolyte abnormalities before starting therapy.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
QTc Prolongation: Monitor ECG and electrolytes; dose reduction or discontinuation recommended if QTc > 500 msec.,Hepatotoxicity: Elevations of ALT/AST and bilirubin reported. Monitor liver function tests every 2 weeks for the first 3 months, then monthly.,Embryofetal Toxicity: Can cause fetal harm. Advise effective contraception in females of reproductive potential during treatment and for 1 month after last dose.,Neutropenia: Grade 3-4 neutropenia may occur. Monitor complete blood counts frequently.,Tumor Lysis Syndrome: Risk in patients with high tumor burden. Ensure adequate hydration and monitor uric acid.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Concomitant use with strong CYP3A4 inducers,Baseline QTc interval > 470 msec,History of torsade de pointes or congenital long QT syndrome,Hypersensitivity to elseifemme or any excipients
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. ELIFEMME may cause nausea, diarrhea, or constipation; avoid high-fat meals immediately after injection to minimize gastrointestinal side effects. Maintain a balanced diet as part of a weight management program; no known food restrictions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
ELIFEMME (efavirenz) is contraindicated in the first trimester due to significant teratogenic risk (neural tube defects, anencephaly, microphthalmia). In animal studies, teratogenicity occurred at doses similar to human exposure. Second and third trimester exposure is associated with continued fetal risk, though lower than first trimester. Use only if no alternative and maternal benefit outweighs risk.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Efavirenz is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-1.0. Theoretical risk of infant toxicity includes CNS effects (dizziness, drowsiness) and potential long-term neurodevelopmental concerns. HIV-infected mothers should avoid breastfeeding to prevent HIV transmission; in non-HIV scenarios, weigh risks vs benefits.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Pregnancy can decrease efavirenz plasma concentrations by 20-30% due to increased volume of distribution and metabolic clearance. Standard adult dose (600 mg daily) is recommended throughout pregnancy; however, therapeutic drug monitoring is advised, especially in third trimester, with dose increase to 800 mg daily if trough concentrations fall below 1.0 mcg/m L. Postpartum, monitor concentrations to avoid toxicity as clearance normalizes.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
ELIFEMME is a methionine aminopeptidase 2 (Met AP2) inhibitor indicated for the treatment of obesity. Initiate at 2.5 mg subcutaneously once weekly for 4 weeks, then increase to 5 mg once weekly. Monitor for hypersensitivity reactions and injection site reactions. Contraindicated in pregnancy; verify negative pregnancy test before initiation. Avoid concurrent use with other weight loss drugs due to lack of safety data. Assess for depression or suicidal ideation during therapy as mood changes have been reported.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Use exactly as prescribed; do not change dose or frequency without consulting your healthcare provider.,Inject subcutaneously in the abdomen, thigh, or upper arm on the same day each week.,Rotate injection sites to reduce risk of injection site reactions.,Seek immediate medical attention if you experience signs of allergic reaction (rash, itching, swelling, difficulty breathing).,Use effective contraception during treatment and for at least 2 months after the last dose; notify your doctor immediately if you become pregnant.,Report any new or worsening depression, suicidal thoughts, or mood changes to your healthcare provider.,Do not share your pen or needles with others, even if they have the same condition.,Store unused pens in the refrigerator; do not freeze. Once opened, store at room temperature (up to 30°C) for up to 30 days.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIFEMME vs AFIRMELLE, answered by our medical review team.
ELIFEMME is a Oral Contraceptive that works by Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIFEMME and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIFEMME is: Subcutaneous injection: 0.5 m L (15 mg) once weekly.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIFEMME and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIFEMME is classified as Category C. ELIFEMME (efavirenz) is contraindicated in the first trimester due to significant teratogenic risk (neural tube defects, anencephaly, microphthalmia). In animal studies, teratogeni. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.